Drug Database
NI

nitroglycerin (Millisrol Tape)

✓ Approved

Nippon Kayaku Co.,Ltd. · Small Molecule · Small Molecule

What is nitroglycerin?

nitroglycerin is a small molecule developed by Nippon Kayaku Co.,Ltd.. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesMillisrol Tape
CompanyNippon Kayaku Co.,Ltd.
Drug ClassSmall Molecule
RouteTransdermal
StatusApproved
Sources: ClinicalTrials.gov, Nippon Kayaku Co.,Ltd.

Therapeutic Indications

nitroglycerin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersAngina pectoris✓ Approved

Related Research Articles

PubMedCureus2026-07-25

Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis.

Rodríguez Dominique D, Rodríguez Manuel M, Andersen Christopher C

An increase in wrinkles, laxity, and dyschromia characterizes facial-skin aging. The skin is a natural barrier that prevents or limits the entry of external therapeutic compounds to the body. Enhancing the efficacy of transdermal delivery of anti-aging compounds is a key therapeutic strategy. The study aimed to evaluate the efficacy and safety of a combined therapy that included a topical anti-aging serum and a multi-technology facial device designed to improve transdermal absorption. A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat. Skin changes were assessed using the VISIA Skin Analysis System (Canfield Scientific, Parsippany, New Jersey) at baseline, 6, and 12 weeks. Both hemifaces showed improvement in skin quality parameters (wrinkles, texture, and UV spots). TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side. Greater improvement in wrinkle reduction was observed on the device-treated side. No adverse events were reported. As a preliminary observation, combined therapy using a topical serum and a multimodal device appears safe and attenuates aging effects, particularly in reducing wrinkles. Further studies are needed to confirm these findings.

PMID 42500768
Read full article →
PubMedBioactive materials2026-07-25

Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.

Xiang Yiming Y, Gong Ziya Z, Liu Juying J, Zhu Yizhou Y et al.

Beyond their conventional role as passive transdermal delivery vehicles, microneedle (MN) platforms now function as active bio-interfaces capable of modulating therapeutic responses in both localized and systemic diseases. This review summarizes recent advances in MN technology, focusing on the transition from traditional matrix-controlled delivery to bioactive microneedles. Although localized applications at barrier surfaces, such as treating cutaneous disorders and mucosal lesions, remain a fundamental focus, this review emphasizes the application of MNs in complex chronic metabolic diseases (e.g., diabetes), oncology (e.g., melanoma and glioblastoma), and deep-tissue degenerative diseases of the cardiovascular, nervous, and musculoskeletal systems. Integrating stimuli-responsive materials, including metal-organic frameworks (MOFs), aggregation-induced emission luminogens (AIEgens), and smart hydrogels, with external physical stimuli enables autonomous, closed-loop interventions, thereby advancing personalized systemic therapy. Furthermore, we summarize recent progress in applying MNs to non-traditional sites and deep-tissue repair. Finally, rather than focusing solely on phenotypic efficacy, we discuss key translational challenges, including manufacturing scalability, biosafety, and regulatory pathways, to guide future clinical translation.

PMID 42499529
Read full article →
PubMedColloids and surfaces. B, Biointerfaces2026-07-25

Crosslinked hybrid micellar platform for targeted cutaneous drug delivery.

Thakur Neeraj S NS, Agrahari Vibhuti V, Kalia Yogeshvar N YN

Micellar systems are transformed upon contact with the stratum corneum lipids, disassembling and releasing their cargo. Thus, the development of micellar systems for sustained cutaneous delivery that retain structural integrity poses considerable challenges. Herein, a highly stable crosslinked hybrid micellar (cHy-Micelles) platform is developed for controlled cutaneous drug delivery. The amine functionalized N-(2-aminoethyl)pentacosa-10,12-diynamide (AMP-1) was synthesized first; then, hybrid micelles were prepared by mixing it with D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) using nanoprecipitation. The micelles were stabilized by UV light irradiation and then characterized to determine morphology, stability, and ability to deliver a cargo. The spherical cHy-micelles with < 50 nm size (37.84 ± 0.45 nm) were highly stable and monodispersed (polydispersity index 0.099 ± 0.004) in the final hydrogel formulation because of intermolecular crosslinking within the micelle. These cHy-micelles also showed excellent cutaneous retention ability and low skin permeation owing to the positive surface potential (ζ potential +42 ± 7.15 mV) - skin has an isoelectric point (pI) of 4-4.5. Interestingly, the targeted cutaneous delivery of poorly water-soluble rose bengal, itraconazole, and clotrimazole was achieved using the developed micelles without showing significant transdermal permeation. This new crosslinked hybrid micellar platform could have enormous potential for topical drug delivery since it could enable modified kinetics as compared to conventional micelles, whilst decreasing the risk of systemic side effects.

PMID 42497476
Read full article →
PubMedInternational journal of pharmaceutics: X2026-07-24

Palonosetron-loaded binary ethosome-incorporated transdermal gel: Formulation optimization, in vitro/in vivo evaluation, and therapeutic efficacy in chemotherapy-induced nausea and vomiting.

Wang Qianru Q, Luo Yu Y, Hu Taomin T, Xiong Wen W et al.

This study aimed to develop a transdermal gel formulation of palonosetron-loaded binary ethosomes (PAL-BE-G) and systematically evaluate its in vitro physicochemical properties, in vivo pharmacodynamics, and pharmacokinetics. PAL-BE was fabricated via the injection-ultrasonication method, and its formulation was optimized using Box-Behnken design. The optimized PAL-BE appeared as a clear, transparent dispersion with pale blue opalescence and exhibited excellent stability at 4 °C. Fourier-transform infrared (FT-IR) spectroscopy verified the formation of hydrogen bonds between palonosetron (PAL) and excipients, with no chemical interactions detected. Subsequently, PAL-BE-G was prepared with 0.5% carbomer 940 as the gel matrix, which maintained favorable storage stability at 4 °C for 120 days. In vitro release assays showed a 94% cumulative release rate of PAL within 36 h, confirming the sustained-release property of the gel. In vitro transdermal permeation studies demonstrated that PAL-BE-G possessed superior skin penetration efficiency. Safety evaluations confirmed the excellent biocompatibility of PAL-BE-G with no significant skin irritation. In vivo pharmacodynamic assays revealed that PAL-BE-G exerted comparable antiemetic efficacy against chemotherapy-induced nausea and vomiting (CINV) to commercial PAL injection. Pharmacokinetic studies indicated that the absolute bioavailability of PAL-BE-G was 18.74 ± 3.26%, with sustained drug release in vivo. In conclusion, the successfully developed PAL-BE-G integrates high transdermal permeability, ideal sustained-release behavior, and favorable safety profiles. It provides a novel therapeutic alternative for CINV patients, especially those unable to tolerate oral administration, and offers experimental and theoretical support for the transdermal delivery of poorly soluble drugs.

PMID 42495157
Read full article →
PubMedCarbohydrate polymers2026-07-24

Cyclodextrin-mediated delivery of resveratrol: Recent advances, therapeutic potential, and future perspectives.

Boroumand Raheleh R, Haghighizadeh Atoosa A, Salmasi Zahra Z, Rajabi Omid O

Resveratrol (RES) is a naturally occurring polyphenol with established antioxidant, anti-inflammatory, anticancer, and cardioprotective properties. However, low aqueous solubility, poor chemical stability, fast metabolism, and low oral bioavailability severely restrict its clinical translation. Cyclodextrins (CDs) and their derivatives, which act as host molecules, can be improved the solubility, stability, and therapeutic efficacy of RES by formation inclusion complexes (ICs). In addition to conventional CDs/RES ICs, various advanced delivery platforms, including CDs-based nanosponges, hybrid nanosystems, and topical/transdermal formulations have demonstrated encouraging outcomes in recent years in terms of enhancing biological activity and modifying release kinetics. Accordingly, a comprehensive understanding of CDs-based platforms for optimizing RES delivery and therapeutic application is necessary. This review highlights the physicochemical basis of the CDs-RES interaction, the mechanisms underlying improved bioavailability, and the effectiveness of CDs-based systems in both in vitro and in vivo models. Moreover, current challenges and future perspectives are discussed to highlight the potential of CDs-enabled strategies for optimizing RES delivery and therapeutic performance.

PMID 42493097
Read full article →
PubMedPain management nursing : official journal of the American Society of Pain Management Nurses2026-07-24

Diclofenac Patches Promote Early Mobilization in Fragility Fractures: A Retrospective Cohort Study.

Saito Mikino M, Higuchi Takashi T

Effective pain management is crucial for the early mobilization and functional recovery of elderly patients with fragility fractures. This study aimed to evaluate the efficacy of transdermal diclofenac patches (DPs) for pain control and their impact on functional recovery, with the primary hypothesis that DPs are superior in shortening the time to mobilization in elderly patients with fragility fractures. Retrospective historical control. This retrospective cohort study with historical controls included patients aged ≥70 years hospitalized with proximal femoral fractures or vertebral fractures. Thirty patients treated with DPs (group D) were compared with 30 patients not treated with DPs (group N). Primary outcomes included time to mobilization, recovery of activities of daily living, and ambulatory ability at discharge. The time to initiating walking practice (mean difference 2.76 days, 95% confidence interval [0.28, 5.23], p = .03) and using the toilet (mean difference 2.37 days, 95% confidence interval [0.00, 4.73], p = .049) was significantly shorter in group D. In the vertebral fracture subgroup, significantly fewer patients in group D showed a decline in walking ability at discharge (p < .05). No drug-related adverse events were observed. DP use was associated with earlier mobilization and better preservation of walking ability. It appears to be a well-tolerated and potentially useful analgesic option for improving the functional outcomes in this high-risk population. However, these findings should be interpreted with caution because of the limitations of unadjusted, nonrandomized historical comparisons. © 20XX by the American Society for Pain Management Nursing.

PMID 42493376
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about nitroglycerin